Lunai Bioworks Inc. (NASDAQ:LNAI – Get Free Report)’s share price was down 2.7% during mid-day trading on Wednesday . The company traded as low as $2.37 and last traded at $2.48. Approximately 102,450 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 476,323 shares. The stock had previously closed at $2.55.
Analyst Ratings Changes
Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a report on Wednesday, July 8th. Wall Street Zen raised Lunai Bioworks to a “sell” rating in a research report on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Lunai Bioworks
Lunai Bioworks Trading Down 2.7%
Lunai Bioworks (NASDAQ:LNAI – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter.
Institutional Investors Weigh In On Lunai Bioworks
A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
Lunai Bioworks Company Profile
Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.
Read More
- Five stocks we like better than Lunai Bioworks
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Lunai Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lunai Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
